Nortis

Nortis is a biotech company that has developed tissue-engineering techniques and organ-on-a-chip systems for the creation of a human micro-tissue environment within small, disposable, microfluidic chips. The company's technology enables living models of human organs that will drastically accelerate the discovery and introduction of new therapies and alleviate the use of lab animals. By growing tissue from human organ systems inside small microfluidic chips, researchers and assay developers can conduct in-vitro testing directly on functional human tissues.  Nortis was founded in 2012 and is headquartered in Woodinville, Washington.

Nortis was a biotech company based in Seattle and Woodinville, Washington that developed technologies for generating small segments of human tissues and organs in microfluidic chips for in vitro study of human health and disease. The company, founded by former University of Washington faculty and spun out in 2011, created microphysiology systems platforms that enabled the generation of patient-derived human microphysiology systems (MPS) based on organoids and induced pluripotent stem cells. These were layered and bioprinted in 3D to implement multiple organ models replicating the heterogeneity of patient diseases. The MPS organ models could be investigated separately or as fluid-coupled organ systems to study disease progression mechanisms and response to prospective therapeutic treatments. Nortis' technology allowed for the safety and efficacy of various therapeutics to be tested in patient-derived MPS models, referred to as "patient biomimetic twins", before being administered to patients.

BioSystics, Inc. merges with Nortis

BioSystics, Inc., a database and analytics company, announced that it has merged with Nortis, a microphysiology systems platform company to form Numa Biosciences, Inc., a precision medicine platform c

Enabling supply of biologically safe tissues and organs using next-gen printing tech

Bioprinting

Organ On A Chip Market Set to Witness Significant Growth by 2024-2031: Organovo, Hepregen, Hurel Corporation, Nortis

Nortis was a biotech company based in Seattle and Woodinville, Washington that developed technologies for generating small segments of human tissues and organs in microfluidic chips for in vitro study of human health and disease. The company, founded by former University of Washington faculty and spun out in 2011, created microphysiology systems platforms that enabled the generation of patient-derived human microphysiology systems (MPS) based on organoids and induced pluripotent stem cells. These were layered and bioprinted in 3D to implement multiple organ models replicating the heterogeneity of patient diseases. The MPS organ models could be investigated separately or as fluid-coupled organ systems to study disease progression mechanisms and response to prospective therapeutic treatments. Nortis' technology allowed for the safety and efficacy of various therapeutics to be tested in patient-derived MPS models, referred to as "patient biomimetic twins", before being administered to patients.
In June 2023, Nortis merged with BioSystics, Inc., a database and analytics company, to form Numa Biosciences, Inc., a precision medicine platform company. The merger aimed to create patient digital twins complementary to the patient biomimetic twins for precision medicine, predicting the most suitable therapeutic treatment for each patient and optimally recruiting clinical trial patient cohorts for specific drug candidates.

3D Bioprinting Solutions is a Russian biotechnology research laboratory focused on developing and commercializing bioprinting technologies. The company was founded by INVITRO, the largest private medical company in Russia, and officially opened its 3D Bioprinting Solutions laboratory in September 2013. Its core activities involve the development and production of bioprinters, bioinks, and biofabrication technologies for regenerative medicine and drug discovery applications.
One of the company's key products is the FABION bioprinter, capable of bioprinting without the need for organic or artificial scaffolds using a proprietary nanotechnology approach. In 2016, 3D Bioprinting Solutions launched the FABION 2, an advanced bioprinter that can print complex structures using tissue spheroids and a wide range of hydrogels with different polymerization mechanisms. The FABION two features a unique laser positioning system with an accuracy of five micrometers, enabling the printing of highly intricate structures.
In 2018, the company delivered its Organ.Aut magnetic 3D bioprinter to the International Space Station (ISS) for conducting experiments in microgravity conditions. The Organ.Aut successfully bioprinted a mouse's thyroid gland in space in December 2018, marking the first instance of living tissue being printed in outer space. In August 2019, the company bioprinted bone tissue aboard the ISS using the Organ.Aut.
3D Bioprinting Solutions has actively pursued collaborations with research institutions and commercial entities worldwide. In April 2019, the company announced plans to collaborate with laboratories from the US and Israel to deliver muscular tissue biomaterials to the ISS for bioprinting experiments using the Organ.Aut bioprinter.

3D Bioprinting Solutions

A.D.A.M. Bioprinting is a company developing an on-demand 3D bioprinting platform for manufacturing personalized implants. Their core technology, a Medical Device Production System, enables medical professionals to complete the entire process of 3D modeling, printing, and sterilization to create customized implants ready for implantation.
The company's initial focus is on producing orthopaedic bone implants for cranial, maxillofacial, general trauma, and orthopaedic oncology surgeries. However, A.D.A.M. Bioprinting plans to expand its offerings to include printed soft tissues in the future.
Founded in 2018, A.D.A.M. Bioprinting has its roots in Ukrainian aerospace and biotech engineering. The company operates with a research and development office in Ukraine, while its US-based entity holds intellectual property and handles business development and marketing functions.
In May 2022, A.D.A.M. Bioprinting was accepted into Elementa Labs, the virtual incubator program of the Mount Sinai Health System in New York. This program aims to optimize, expand, and advance the company's core technology platform, potentially leading to its commercialization in the US market.

A.D.A.M.

Advanced BioMatrix, a San Diego-based biotechnology company, develops advanced biomaterials and reagents for 3D cell culture applications, including cell cultivation, cell assays, bioprinting, and cell proliferation. The company's products have been utilized in groundbreaking research for drug development and 3D bioprinted tissue models, with over 5,000 citations in scientific publications as of September 2021. Advanced BioMatrix's offerings include hydrogels that mimic the extracellular matrix, facilitating cellular attachment, survival, and compatibility with various tissue types.
In September 2021, Advanced BioMatrix was acquired by BICO Group AB, a Swedish bioconvergence company focused on enhancing biology research, for approximately USD 15 million. Following the acquisition, Advanced BioMatrix became a subsidiary of CELLINK Bioprinting, operating under the BICO Group. The company generated approximately USD 3 million in revenue with an adjusted EBITDA margin of around 50% in its latest fiscal year prior to the acquisition.
Key customers and partnerships
Advanced BioMatrix has established collaborations with research institutes, pharmaceutical companies, and life science organizations worldwide. In June 2022, the company expanded its existing partnership with Lineage Cell Therapeutics for Lineage's HyStem cell/drug delivery technology, broadening its focus on manufacturing and supplying research-grade HyStem to the research community and developing clinical/commercial-grade material for Lineage's customers.
In August 2023, Advanced BioMatrix signed a distribution agreement with InSphero AG, a pioneer in 3D cell culture and organ-on-chip technology, to make InSphero's patented Akura Plate Technology available to researchers in the US market. This collaboration aims to expand the application range for scientists and drug developers by combining Advanced BioMatrix's biomaterials with InSphero's Akura Plates for scaffold-based organoid and spheroid cultures.

Advanced Biomatrix

Advanced Solutions Life Sciences, a wholly-owned subsidiary of Advanced Solutions, Inc., is a global leader in 3D biofabrication, headquartered in Louisville, Kentucky. The company pioneered the BioAssemblyBot, the world's first 6-axis robotic human tissue printer capable of systematically reproducing organoids. Their patented 3D printed blood vessel technology, derived from human fat tissue, empowers customers to advance the science of 3D organ printing. Advanced Solutions Life Sciences offers expertise in regenerative medicine, bioinks, 3D tissue assays for drug discovery and testing, 3D tissue modeling, and 3D printing services.
In May 2018, the company expanded its operations by opening a second biofabrication facility and laboratory in Manchester, New Hampshire. This strategic expansion aimed to contribute to curative organ printing solutions and establish the company as a prominent corporate citizen in Manchester.
In January 2023, Advanced Solutions Life Sciences partnered with Molecular Devices, a bioscience company, to develop 3D biology automation solutions. They jointly developed the BioAssemblyBot 400 (BAB 400) for Drug Discovery, integrating Advanced Solutions' bioprinting platform with Molecular Devices' ImageXpress Cellular Imaging System. This automated platform enables consistent, large-scale production of organoid models, enhancing drug discovery research.

Advanced Solutions Life Sciences

Allegro 3D is a bioprinting company specializing in high-throughput and high-precision 3D printing technology for fabricating tissue models at an industrial scale. The company was acquired by BICO, a Swedish bioconvergence company, in May 2022 for an upfront enterprise value of USD 6 million. Allegro 3D's patented light-based digital light processing (DLP) bioprinting technology enables direct printing into multi-well plates, allowing customers to significantly increase their output of biofabricated constructs for applications in regenerative medicine and drug discovery workflows. The company's flagship product, the STEMAKER Model D, utilizes extrusion-based bioprinting to produce bio/organic parts using liquid feedstock. As of 2022, Allegro 3D was expected to generate approximately USD 1 million in revenue with positive EBITDA margins. The acquisition complements BICO's existing portfolio of bioprinters and strengthens its position as a global leader in providing bioprinting solutions.

Allegro 3D

Developing and selling bioprinter devices that can be used by hospitals, research institutes, and other organizations seeking to print biological substitutes and materials.

Companies that use propietary or third-party printers to produce and sell bioprinted tissues, including impants, organ replacement, and other types of tissues.

Companies that are developing materials and bioinks, that can be used in bioprinting devices. This includes material technologies and nanofibers.

Developing software solutions and applications for designing and managing the bioprinting production process.

3D printing enables bioprinting devices, which rely on a similar design and operating model

Startups in this hub are able to customize the bioprinted models to suit each patient

AI/ML is used in the design and optimization of 3D models that can be bioprinted

Nortis

Sources

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless